Galectin Therapeutics

Galectin Therapeutics(GALT)

NORCROSS, GA
Biotechnology

Focus: Small Molecules

Galectin Therapeutics is a life sciences company focused on Small Molecules.

OncologyInfectious DiseasesCardiovascularGastroenterologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

1 mg/kg GR-MD-02
Metastatic Melanoma
Phase 1
Clinical Trials (1)
NCT02117362Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase 1
Phase 1
Clinical Trials (1)
NCT00054977Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
Phase 1
GR-MD-02
Melanoma
Phase 1
Clinical Trials (1)
NCT02575404GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Phase 1
Clinical Trials (1)
NCT01899859Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Phase 1
Phase 1
Clinical Trials (1)
NCT04332432A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
Phase 1
GM-CT-01 plus 5-Fluorouracil
Colorectal Cancer
Phase 2
Clinical Trials (1)
NCT00110721GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
Phase 2
GR-MD-02
Psoriasis
Phase 2
Clinical Trials (1)
NCT02407041An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Phase 2
Clinical Trials (1)
NCT00386516Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT02462967Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Phase 2
Phase 2
Clinical Trials (1)
NCT00388700A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Phase 2
Clinical Trials (1)
NCT02421094Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase 2
Clinical Trials (1)
NCT04365868Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 12 clinical trials
SEC Filings: 2 available

Financials (FY2024)

R&D Spend
$32M1%
Net Income
-$41M
Cash
$26M